Investor Presentaiton
For personal use only
Executive summary
First commercial product
now approved in the US
•
•
TELIX
PHARMACEUTICALS
US FDA approval received December 2021
Commercial launch ready in US and AU from late Q1, 2022
Additional global approvals expected in EU/UK and Canada
Clear growth strategy to
unlock value in the pipeline
Use Illuccix as a commercial launchpad
Build a high-value diagnostics portfolio
Deliver on commercial value of therapeutics
Expand the pipeline
$200M capital raise to advance
diagnostic and therapeutic programs
$175M placement + $25M share purchase plan
Co-founder Sell-Down of four million shares
Priced at $7.70 per share
To fund late-stage clinical programs & pipeline expansion
Telix Pharmaceuticals Limited (ASX: TLX)View entire presentation